dc.contributor.author | Fernández-Medina, T | |
dc.contributor.author | Vaquette, C | |
dc.contributor.author | Ivanovski, S | |
dc.date.accessioned | 2020-01-13T02:25:19Z | |
dc.date.available | 2020-01-13T02:25:19Z | |
dc.date.issued | 2019 | |
dc.identifier.issn | 1661-6596 | |
dc.identifier.doi | 10.3390/ijms20246243 | |
dc.identifier.uri | http://hdl.handle.net/10072/390139 | |
dc.description.abstract | Hemoderivatives have utilized in an empirical manner, driven by clinical considerations, leading to the development of a plethora of manufacturing protocols. The purpose of this study was to investigate the composition and bioactivity of four common clinical-grade hemoderivates prepared using standardised methods. Four different hemoderivatives were obtained from sheep blood and divided into two groups: A-PRF/i-PRF (fresh) and P-PRP/L-PRP (anticoagulated). Thrombus (CLOT) was used as a control. Thrombocyte quantification, growth factor composition (IGF-I, VEGF, PDGF-BB, BMP-2), cell viability, migration and mineralization assay were evaluated. Platelet recovery was superior for L-PRP followed by P-PRP. A significant cumulative release of IGF-I and PDGF-BB was noted for A-PRF and L-PRP groups at early time points. Similar release profiles of BMP-2 and VEGF were noted in all protocols. Cell viability and migration assay have demonstrated a detrimental effect when the concentration was ≥60%. Moreover, at Day 21, i-PRF have demonstrated superior mineralisation properties when compared to all groups. A negative impact of A-PRF was demonstrated at high concentrations. Despite its low content in growth factors, i-PRF was the best performing blood product for inducing osteoblast mineralisation, and therefore could be the candidate of choice for utilisation in bone tissue engineering applications. | |
dc.description.peerreviewed | Yes | |
dc.language | English | |
dc.language.iso | eng | |
dc.publisher | Multidisciplinary Digital Publishing Institute (MDPI) | |
dc.publisher.place | Switzerland | |
dc.relation.ispartofpagefrom | 6243: 1 | |
dc.relation.ispartofpageto | 6243: 19 | |
dc.relation.ispartofissue | 24 | |
dc.relation.ispartofjournal | International Journal of Molecular Sciences | |
dc.relation.ispartofvolume | 20 | |
dc.subject.fieldofresearch | Other chemical sciences | |
dc.subject.fieldofresearch | Genetics | |
dc.subject.fieldofresearch | Other biological sciences | |
dc.subject.fieldofresearchcode | 3499 | |
dc.subject.fieldofresearchcode | 3105 | |
dc.subject.fieldofresearchcode | 3199 | |
dc.subject.keywords | bone formation | |
dc.subject.keywords | growth factors | |
dc.subject.keywords | platelet rich fibrin | |
dc.subject.keywords | platelet rich plasma | |
dc.subject.keywords | standardisation | |
dc.title | Systematic Comparison of the Effect of Four Clinical-Grade Platelet Rich Hemoderivatives on Osteoblast Behaviour | |
dc.type | Journal article | |
dc.type.description | C1 - Articles | |
dcterms.bibliographicCitation | Fernández-Medina, T; Vaquette, C; Ivanovski, S, Systematic Comparison of the Effect of Four Clinical-Grade Platelet Rich Hemoderivatives on Osteoblast Behaviour, International Journal of Molecular Sciences, 2019, 20 (24), pp. 6243: 1-6243: 19 | |
dcterms.dateAccepted | 2019-12-09 | |
dcterms.license | https://creativecommons.org/licenses/by/4.0/ | |
dc.date.updated | 2020-01-13T01:49:12Z | |
dc.description.version | Version of Record (VoR) | |
gro.rights.copyright | © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. | |
gro.hasfulltext | Full Text | |
gro.griffith.author | Ivanovski, Saso | |